Last Price$1.57NASDAQ Closing Price as of 4:00PM ET 5/23/22
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0.00(0.00%)
Bid (Size)$1.56 (165)
Ask (Size)$1.57 (98)
Day Low / High$1.56 - 1.62
Volume2.3 M

View Biotechnology IndustryPeer Comparison as of 05/23/2022


Agenus Inc ( NASDAQ )

Price: $1.57
Change: 0.00 (0.00%)
Volume: 2.3 M
4:00PM ET 5/23/2022

MiMedx Group Inc ( NASDAQ )

Price: $3.56
Change: -0.04 (1.11%)
Volume: 391.3 K
4:00PM ET 5/23/2022

ADMA Biologics Inc ( NASDAQ )

Price: $2.07
Change: +0.03 (1.47%)
Volume: 1.4 M
4:00PM ET 5/23/2022

Rapt Therapeutics Inc ( NASDAQ )

Price: $12.56
Change: -0.88 (6.55%)
Volume: 151.9 K
4:00PM ET 5/23/2022

MeiraGTx Holdings PLC ( NASDAQ )

Price: $8.19
Change: -0.52 (5.97%)
Volume: 146.6 K
4:00PM ET 5/23/2022

Read more news Recent News

Agenus Says Gilead Hits Clinical Milestone for Melanoma Drug Candidate, Triggering $5 Million Payment
10:20AM ET 4/05/2022 MT Newswires

Agenus (AGEN) said Tuesday its collaboration partner Gilead Sciences (GILD) has achieved a clinical milestone for melanoma drug candidate AGEN2373,...

Agenus to Supply Adjuvant Under Cancer Vaccine Clinical Collaboration With Targovax ASA
8:16AM ET 3/07/2022 MT Newswires

Agenus (AGEN) has entered a clinical collaboration and supply agreement to combine its QS-21 Stimulon adjuvant with clinical stage biotechnology company...

--B. Riley Lowers Agenus' Price Target to $8 from $11, Keeps Buy Rating
9:49AM ET 3/03/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

--HC Wainwright Adjusts Agenus' Price Target to $14 from $12, Reiterates Buy Rating
11:07AM ET 3/02/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

View all Commentary and Analysis

Agenus Inc. (AGEN) CEO Garo Armen on Q1 2022 Results - Earnings Call Transcript
3:44PM ET 5/10/2022 Seeking Alpha

Agenus: Not Quite Enough
8:30AM ET 4/19/2022 Seeking Alpha

Biotech 101 Lecture 3: Looking At Major Biotech Catalysts
3:23PM ET 3/08/2022 Seeking Alpha

Agenus Inc. 2021 Q4 - Results - Earnings Call Presentation
5:18AM ET 3/02/2022 Seeking Alpha

Company Profile

Business DescriptionAgenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 31, 1994 and is headquartered in Lexington, MA. View company web site for more details
Address3 Forbes Road
Lexington, Massachusetts 02421-7305
Number of Employees294
Recent SEC Filing05/10/20228-K
Chairman & Chief Executive OfficerGaro H. Armen
Chief Financial & Accounting Officer, VP-FinanceChristine M. Klaskin
Chief Medical OfficerSteven O’Day
Chief Information OfficerCraig Winter

Company Highlights

Price Open$1.61
Previous Close$1.57
52 Week Range$1.46 - 6.79
Market Capitalization$425.5 M
Shares Outstanding271.0 M
SectorHealth Technology
Next Earnings Announcement08/08/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.07
Beta vs. S&P 500N/A
Revenue$36.8 M
Net Profit Margin-5.99%
Return on Equity54.30%

Analyst Ratings as of 12/15/2021

Consensus RecommendationConsensus Icon
Powered by Factset